Scanmed Acquires Ars Medical

Scanmed, a Warsaw, Poland-based healthcare firm, acquired Ars Medical, one other Polish most cancers care remedy firm.

The quantity of the deal, supported by Abris Capital Partners, was not disclosed.

With the acquisition, Scanmed will develop into the biggest unbiased healthcare supplier in Poland. The deal will broaden Scanmed’s provide to accommodate the wants of its shoppers and can strengthen its place as a personal in-patient healthcare supplier. Additionally, the acquisition will allow synergies with present Scanmed services and increase the corporate’s presence in north-west Poland.

Led by CEO Dr Zygmunt Malinowski, Ars Medical specialises in oncology, haematology, cardiology, inside medication and palliative care, in addition to basic and specialist outpatient care. The firm is an area gamers in most cancers care remedy, diagnostic imaging and business procedures, and has a staff of 400 medical doctors and nurses, together with over 100 specialists in 48 therapeutic areas. 

Led by CEO Andrzej Podlipski, Scanmed is a healthcare suppliers in Poland, providing a variety of medical providers inside main care, outpatient specialist consultations, diagnostics and inpatient/hospital remedy. Scanmed Group affords its sufferers an entry to complete therapeutic strategies, technologically superior and medical gear and skilled specialists to facilitate their restoration. The group operates in additional than 40 areas throughout Poland and runs the next medical services: two multi-specialist hospitals: St. Raphael in Krakow and Rudolf Weigl in Blachownia, 13 cardiac cath labs, three well-recognised inpatient clinics: Gastromed in Lublin, Sport-Klinika in Żory and Weiss Klinik in Chorzów.

Abris acquired Scanmed in 2020 with a plan to construct an area healthcare champion by bettering and rising the group’s service providing in key therapeutic areas together with cardiology, oncology, orthopedics and ophthalmology, and increase its countrywide geographic protection. 

FinSMEs

24/11/2022

Leave a Comment